ログイン

Pharmacokinetics (1.1)

Pharmacokinetics (1.1)
100問 • 2年前
  • Quinn Karylle Fuentes
  • 通報

    問題一覧

  • 1

    The processes of a drug from the systemic circulation to organs and tissue involve its permeation through membrane barriers and are dependent on its solubility (recall that only nonionized drugs cross biomembranes), the rate of blood flow to the tissues, and the binding of drug molecules to plasma proteins.

    Distribution

  • 2

    What are the factors affecting distribution?

    Rate and Extent Distribution

  • 3

    -Membrane permeability - Capillary wall structure - Drug’s pKa and blood pH - Blood Perfusion

    Rate of distribution.

  • 4

    - Lipid solubility - pH-pKa - Tissue localization - Plasma-protein binding

    Extent of distribution.

  • 5

    DRUG MOLECULES are carried by the blood to the target site (receptors) and to nonreceptor tissues

    Distribution.

  • 6

    DRUG + PROTEIN (ALBUMIN) = DRUG ALBUMIN COMLEX (pharmacologically inactive)

    Protein binding capacity.

  • 7

    drug that is unbound to plasma proteins. Only the “unbound” or free drug is available to distribute out of blood vessels and act on the body cells to elicit the desired effect

    Free drug.

  • 8

    - Major plasma protein component . - Reversible drug binding . - Acidic drugs.

    Albumin.

  • 9

    Alpha-1 Acid Glycoprotein (AAG) and Globulin

    Basic drugs.

  • 10

    - macromolecular complexes of lipids + proteins - Binds drugs when albumin sites become saturated

    Lipoprotein

  • 11

    May bind both endogenous and exogenous compounds

    RBC

  • 12

    May be responsible for the transport of certain endogenous substances such as corticoste

    Globulin

  • 13

    The most abundant protein in human blood plasma

    Albumin

  • 14

    produced in the liver. soluble and monomeric.

    Albumin

  • 15

    Responsible for maintaining the osmotic pressure of the blood.

    Albumin

  • 16

    Elimination half life 17 – 18 days Reversible binding Synthesized in the liver

    Albumin

  • 17

    MW 44,000Da Low plasma concentration(0.4- 1%) binds primarly basic (cationic) drugs.

    A-acid glycoprotein

  • 18

    Macromolecular complexes lipids and protein Classified accdg. to their density and separation in the ultracentrifuge.

    Lipoprotein

  • 19

    Responsible for the transport of plasma liquids to the liver. Resp. for binding if albumin is saturated

    Lipoprotein

  • 20

    45 % of the total volume May bind both endogenous and exogenous compounds.

    Erythrocytes

  • 21

    Αβγ globulins Transport certain endogenous subs (corticosteroid) Ppt in both distilled water and 50% sat. Ammonium SO4

    Globulins

  • 22

    -Physicochemical nature - Concentration in the body

    Drug

  • 23

    - Qty available for binding - Quality of protein synthesized - Affinity between drug & protein

    Protein

  • 24

    - Competition at binding sites - Alteration of the protein by a substance that modifies the affinity of a drug for the protein

    Drug interactions

  • 25

    Tissues with decrease regional blood flow (bones, adipose tissues, middle ear)

    Blood flow

  • 26

    Areas of high blood flow

    Heart, liver, kidney and brain

  • 27

    Areas of low blood flow:

    Muscle, skin, fat and bone

  • 28

    BBB and PLACENTAL BARRIER Allows only non-ionized, unbound drug to enter brain.

    Ability to cross membranes.

  • 29

    The chemical process by which the body converts an agent from its original form to a more water-soluble form that can be excreted

    Metabolism

  • 30

    most important site of drug metabolism, but it may also occur in renal tissue, lungs, plasma or intestinal mucosa.

    Liver

  • 31

    the major site of metabolism for the majority of drugs

    Liver

  • 32

    hydrolysis, mainly of esters

    Plasma and body fluids

  • 33

    metabolism of endogenous transmitters and drugs with similar structures

    Nerve terminals

  • 34

    responsible for pre-systemic metabolism of many drugs

    Mucosal cells

  • 35

    metabolize some drugs

    Kidney, lungs and muscle

  • 36

    capable of glucuronidation of morphine

    Brain

  • 37

    metabolism of several drugs and hydrolysis of glucuronide metabolites.

    Intestinal bacteria.

  • 38

    metabolic conversion of drugs, generally to less active compounds but sometimes to isoactive or more active forms.

    Biotransformation.

  • 39

    the phenomenon whereby drugs may be metabolized following absorption before reaching systemic circulation

    First pass effect

  • 40

    Include oxidation (especially by the cytochrome P45- group of enzymes also called mixed function oxidases), reduction, deamination and hydrolysis

    Phase 1

  • 41

    Reactions that convert the parent drug to a more polar (watersoluble) or more reactive product by unmasking or inserting a polar functional group such as -OH, -SH, or -NH

    Phase 1.

  • 42

    Polar functional groups are introduced into the molecule or unmasked by

    Oxidation, reduction and hydrolysis

  • 43

    -loss of electrons - reducing agents - dehydrogenation - increase in oxidation state

    Oxidation

  • 44

    A heme protein with iron protoporphyrin IX as the prosthetic group

    Cytochrome 450

  • 45

    These enzymes require a reducing agent (NADPH) and molecular oxygen (one oxygen atom appearing in the product and the other in the form of water)

    Microsomal oxidation

  • 46

    Mono Amine Oxidase (ex. Serotonin, Epinephrine, Norepinephrine, Dopamine, Tyramine)

    CYP independent oxidation

  • 47

    Xanthine oxidase

    CYP independent oxidation

  • 48

    -gain of electrons - oxidizing agents - hydrogenation - decrease in oxidation state

    Reduction

  • 49

    Nitro reduction (ex)

    Chlorampenicol

  • 50

    Carbonyl reduction (ex)

    Naloxone

  • 51

    Azo reduction. (ex)

    Protonsil (Sulfonamides).

  • 52

    Dehalogenation.( ex)

    Halothane

  • 53

    Splitting of large molecule involving water as solvent

    Hydrolysis

  • 54

    Examples of hydrolysis.

    Amide and Ester.

  • 55

    Hydrolysis used for?

    Local anesthetic

  • 56

    Synthetic reactions that involve addition (conjugation) of subgroups to -OH, -NH 2, and -SH functions on the drug molecule.

    Phase 2.

  • 57

    The subgroups that are added include glucuronate, acetate, glutathione, glycine, sulfate, and methyl groups.

    Phase 2.

  • 58

    Most of these groups are relatively polar and make the product less lipid-soluble than the original drug molecule.

    Phase 2.

  • 59

    This metabolism phase reaction is responsible for the formation of the final metabolic product of the drug to be excreted

    Phase 2.

  • 60

    relatively water soluble and readily excretable biologically inactive and nontoxic

    Phase 2.

  • 61

    Do not generally increase water solubility but mainly to serve to terminate or attenuate pharmacological activity.

    Phase 2.

  • 62

    a condensation of the drug or its primary metabolite with glucoronic acid.

    Glucoronidation

  • 63

    The reaction requires activation of glucoronic acid by synthesis of UDPGA

    Glucoronidation

  • 64

    Drugs that compete for glucuronidation or reduce the already low glucuronyl transferase activity can precipitate Kernicterus.

    True.

  • 65

    Caused by Chloramphenicol given to neonates

    Grey baby syndrome.

  • 66

    Caused by Chloramphenicol given to neonates

    Grey baby syndrome.

  • 67

    The human newborn is already capable of sulfate conjugation but this pathway becomes easily saturated due to limited sulfate pool

    Sulfation.

  • 68

    The sulfate pool in the organism is limited and easily depleted. PAPS transfer the sulfate to the drug molecule in the soluble fraction of the cell.

    Sulfation.

  • 69

    Sulfation.

    Birth.

  • 70

    1st week

    Oxidation and reduction.

  • 71

    1 month .

    acetylation

  • 72

    2 months.

    Glucoronidation

  • 73

    3 months.

    Glycerin conjugate.

  • 74

    most common endogenous amine for conjugation with organic acids.

    Glycerin

  • 75

    Takes place usually in the mitochondrial fraction. However, bile acids are conjugated with glycine in the microsomal fraction

    Glycerin conjugation.

  • 76

    Newborns and aged have a reduced glycine pool

    Glycerin conjugation.

  • 77

    available in man for conjugation with organic acids, such as phenylacetic and related acids.

    Glutamine

  • 78

    for glutamine conjugation is localized in the liver and kidney

    Acylating enzyme.

  • 79

    Conjugation by acetylation of aromatic primary amines, aliphatic amines, amino acids, hydrazines (-NHNH2), hydrazides (-CONHNH2) and sulfonamides occurs in many tissues

    True.

  • 80

    The newborn is not capable of acetylation. The presence of the various acetyl transferases is genetically determined (slow acetylation and fast acetylators

    True.

  • 81

    Side effect of Procainamide SLE (systemic lupus erythematosus

    Butterfly rash.

  • 82

    It is only a minor pathway for conjugating drugs and xenobiotics.

    Methylation.

  • 83

    It generally does not lead to polar or water-soluble metabolites, except when it creates a quaternary ammonium derivative.

    Methylation.

  • 84

    Most methylated products tend to be pharmacologically inactive except for some.

    True.

  • 85

    Drug or chemical-stimulated increase in enzyme activity.

    Enzyme induction.

  • 86

    Alteration in the enzyme activity in liver microsomes resulting in a faster rate of metabolism not a disease; it is an adaptation of the body to exogenous material

    Enzyme induction.

  • 87

    A drug that stimulates its own metabolism

    Auto induction.

  • 88

    Phenobarbital is given repeatedly its metabolism is increased

    Auto induction.

  • 89

    Types of emzye induction.

    Auto and foreign.

  • 90

    one enzyme inducer stimulate the rate of metabolism of another drug

    Foreign induction.

  • 91

    If a dose of hexobarbital is then given its metabolism is also increased

    Foreign induction.

  • 92

    May be due to substrate competition or due to direct inhibition of drug metabolizing enzyme

    Enzyme inhibition.

  • 93

    ↓enzyme↓ metabolism ↑ effect

    Enzyme inhibition.

  • 94

    ↑enzymes ↑ metabolism ↓ effect

    Enzyme induction.

  • 95

    the final elimination of the drug substance or its metabolites from the body such as through: 1) The kidney (urine) 2) intestines (feces) 3) skin (sweat) 4) saliva, and/or milk

    Excretion

  • 96

    Located in the peritoneal cavity and most important organ for excretion

    Kidney

  • 97

    -maintain normal fluid volume - maintain salt and water balance with 2 endocrine function

    Kidney

  • 98

    Responsible for the removal of metabolic waste and the maintenance of water and electrolyte balance

    Nephrons

  • 99

    Anions, cations, non-ionized molecules with lipophilic polar groups & those with MW>500

    Biliary excretion

  • 100

    - For drugs poorly absorbed in the intestines - Organic acids & organic bases à active transport - Consider biliary recycling

    Biliary Excretion

  • Cell structure.

    Cell structure.

    Quinn Karylle Fuentes · 28問 · 2年前

    Cell structure.

    Cell structure.

    28問 • 2年前
    Quinn Karylle Fuentes

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    Quinn Karylle Fuentes · 29問 · 2年前

    Electrolytes and non electrolytes

    Electrolytes and non electrolytes

    29問 • 2年前
    Quinn Karylle Fuentes

    MW

    MW

    Quinn Karylle Fuentes · 45問 · 2年前

    MW

    MW

    45問 • 2年前
    Quinn Karylle Fuentes

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    Quinn Karylle Fuentes · 38問 · 2年前

    POST LAB (EXP 4)

    POST LAB (EXP 4)

    38問 • 2年前
    Quinn Karylle Fuentes

    Density and specific gravity

    Density and specific gravity

    Quinn Karylle Fuentes · 34問 · 2年前

    Density and specific gravity

    Density and specific gravity

    34問 • 2年前
    Quinn Karylle Fuentes

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    Quinn Karylle Fuentes · 18問 · 2年前

    FORCES OF ATTRACTION

    FORCES OF ATTRACTION

    18問 • 2年前
    Quinn Karylle Fuentes

    Microbial growth

    Microbial growth

    Quinn Karylle Fuentes · 63問 · 2年前

    Microbial growth

    Microbial growth

    63問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 61問 · 2年前

    Introduction.

    Introduction.

    61問 • 2年前
    Quinn Karylle Fuentes

    Microbial control.

    Microbial control.

    Quinn Karylle Fuentes · 97問 · 2年前

    Microbial control.

    Microbial control.

    97問 • 2年前
    Quinn Karylle Fuentes

    States of matter

    States of matter

    Quinn Karylle Fuentes · 100問 · 2年前

    States of matter

    States of matter

    100問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 86問 · 2年前

    Introduction.

    Introduction.

    86問 • 2年前
    Quinn Karylle Fuentes

    Drug development.

    Drug development.

    Quinn Karylle Fuentes · 77問 · 2年前

    Drug development.

    Drug development.

    77問 • 2年前
    Quinn Karylle Fuentes

    CGMP

    CGMP

    Quinn Karylle Fuentes · 9問 · 2年前

    CGMP

    CGMP

    9問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    Quinn Karylle Fuentes · 24問 · 2年前

    Pharmaceutical ingredients.

    Pharmaceutical ingredients.

    24問 • 2年前
    Quinn Karylle Fuentes

    Powdered & granules

    Powdered & granules

    Quinn Karylle Fuentes · 43問 · 2年前

    Powdered & granules

    Powdered & granules

    43問 • 2年前
    Quinn Karylle Fuentes

    Capsule.

    Capsule.

    Quinn Karylle Fuentes · 24問 · 2年前

    Capsule.

    Capsule.

    24問 • 2年前
    Quinn Karylle Fuentes

    Tablets.

    Tablets.

    Quinn Karylle Fuentes · 23問 · 2年前

    Tablets.

    Tablets.

    23問 • 2年前
    Quinn Karylle Fuentes

    Calculatiom of dose

    Calculatiom of dose

    Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

    Calculatiom of dose

    Calculatiom of dose

    3回閲覧 • 66問 • 2年前
    Quinn Karylle Fuentes

    Postlab 5&6

    Postlab 5&6

    Quinn Karylle Fuentes · 29問 · 2年前

    Postlab 5&6

    Postlab 5&6

    29問 • 2年前
    Quinn Karylle Fuentes

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    Quinn Karylle Fuentes · 33問 · 2年前

    COLLIGATIVE PROPERTIES.

    COLLIGATIVE PROPERTIES.

    33問 • 2年前
    Quinn Karylle Fuentes

    SEMI SOLID

    SEMI SOLID

    Quinn Karylle Fuentes · 69問 · 2年前

    SEMI SOLID

    SEMI SOLID

    69問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology

    Basic immunology

    Quinn Karylle Fuentes · 60問 · 2年前

    Basic immunology

    Basic immunology

    60問 • 2年前
    Quinn Karylle Fuentes

    Basic immunology (2)

    Basic immunology (2)

    Quinn Karylle Fuentes · 62問 · 2年前

    Basic immunology (2)

    Basic immunology (2)

    62問 • 2年前
    Quinn Karylle Fuentes

    Transdermal

    Transdermal

    Quinn Karylle Fuentes · 44問 · 2年前

    Transdermal

    Transdermal

    44問 • 2年前
    Quinn Karylle Fuentes

    Distribution.

    Distribution.

    Quinn Karylle Fuentes · 43問 · 2年前

    Distribution.

    Distribution.

    43問 • 2年前
    Quinn Karylle Fuentes

    Infectious disease.

    Infectious disease.

    Quinn Karylle Fuentes · 65問 · 2年前

    Infectious disease.

    Infectious disease.

    65問 • 2年前
    Quinn Karylle Fuentes

    Infectious diseases (2)

    Infectious diseases (2)

    Quinn Karylle Fuentes · 79問 · 2年前

    Infectious diseases (2)

    Infectious diseases (2)

    79問 • 2年前
    Quinn Karylle Fuentes

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    Quinn Karylle Fuentes · 35問 · 2年前

    Gram positive ( Bacteriology)

    Gram positive ( Bacteriology)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    Quinn Karylle Fuentes · 35問 · 2年前

    All topic. ( Compressed.)

    All topic. ( Compressed.)

    35問 • 2年前
    Quinn Karylle Fuentes

    All topic ( Compressed)

    All topic ( Compressed)

    Quinn Karylle Fuentes · 30問 · 2年前

    All topic ( Compressed)

    All topic ( Compressed)

    30問 • 2年前
    Quinn Karylle Fuentes

    All topics (compressed)

    All topics (compressed)

    Quinn Karylle Fuentes · 13問 · 2年前

    All topics (compressed)

    All topics (compressed)

    13問 • 2年前
    Quinn Karylle Fuentes

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    Quinn Karylle Fuentes · 28問 · 2年前

    Exercise 6 ; Isotonic solution.

    Exercise 6 ; Isotonic solution.

    28問 • 2年前
    Quinn Karylle Fuentes

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    Quinn Karylle Fuentes · 16問 · 2年前

    Exercise 5 : Buffers.

    Exercise 5 : Buffers.

    16問 • 2年前
    Quinn Karylle Fuentes

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    Quinn Karylle Fuentes · 26問 · 2年前

    Exercise 7 : Factors affecting solubility.

    Exercise 7 : Factors affecting solubility.

    26問 • 2年前
    Quinn Karylle Fuentes

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    Quinn Karylle Fuentes · 23問 · 2年前

    Experiment 8: Disintegration.

    Experiment 8: Disintegration.

    23問 • 2年前
    Quinn Karylle Fuentes

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Quinn Karylle Fuentes · 35問 · 2年前

    Experiment 9 ; Interfacial phenomenon and surface tension.

    Experiment 9 ; Interfacial phenomenon and surface tension.

    35問 • 2年前
    Quinn Karylle Fuentes

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 9 : Aromatic ammonia spirit.

    EXP 9 : Aromatic ammonia spirit.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    Quinn Karylle Fuentes · 34問 · 2年前

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

    34問 • 2年前
    Quinn Karylle Fuentes

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    Quinn Karylle Fuentes · 20問 · 2年前

    EXP 12: ACACIA MUCILAGE

    EXP 12: ACACIA MUCILAGE

    20問 • 2年前
    Quinn Karylle Fuentes

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    Quinn Karylle Fuentes · 33問 · 2年前

    EXP13&14 : Starch and Barrium sulfate.

    EXP13&14 : Starch and Barrium sulfate.

    33問 • 2年前
    Quinn Karylle Fuentes

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    Quinn Karylle Fuentes · 37問 · 2年前

    EXP 15 : Liquid petroleum emulsion 1.0

    EXP 15 : Liquid petroleum emulsion 1.0

    37問 • 2年前
    Quinn Karylle Fuentes

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    Quinn Karylle Fuentes · 23問 · 2年前

    EXP 15: Liquid petroleum emulsion 1.1

    EXP 15: Liquid petroleum emulsion 1.1

    23問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae

    Enterobacteriaceae

    Quinn Karylle Fuentes · 35問 · 2年前

    Enterobacteriaceae

    Enterobacteriaceae

    35問 • 2年前
    Quinn Karylle Fuentes

    Enterobacteriaceae.

    Enterobacteriaceae.

    Quinn Karylle Fuentes · 28問 · 2年前

    Enterobacteriaceae.

    Enterobacteriaceae.

    28問 • 2年前
    Quinn Karylle Fuentes

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    Quinn Karylle Fuentes · 31問 · 2年前

    LIQUID DOSAGE FORM 1.0

    LIQUID DOSAGE FORM 1.0

    31問 • 2年前
    Quinn Karylle Fuentes

    Liquid dosage form

    Liquid dosage form

    Quinn Karylle Fuentes · 12問 · 2年前

    Liquid dosage form

    Liquid dosage form

    12問 • 2年前
    Quinn Karylle Fuentes

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    Quinn Karylle Fuentes · 44問 · 2年前

    MICROMERITICS 1.0

    MICROMERITICS 1.0

    44問 • 2年前
    Quinn Karylle Fuentes

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    Quinn Karylle Fuentes · 22問 · 2年前

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

    22問 • 2年前
    Quinn Karylle Fuentes

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    Quinn Karylle Fuentes · 40問 · 2年前

    EXP 8 : KIRBY-BAUER TECHNIQUE

    EXP 8 : KIRBY-BAUER TECHNIQUE

    40問 • 2年前
    Quinn Karylle Fuentes

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    Quinn Karylle Fuentes · 29問 · 2年前

    EXP 9: STAPHYLOCOCCI

    EXP 9: STAPHYLOCOCCI

    29問 • 2年前
    Quinn Karylle Fuentes

    Drug incompatibilities.

    Drug incompatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug incompatibilities.

    Drug incompatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    Drug compatibilities.

    Drug compatibilities.

    Quinn Karylle Fuentes · 41問 · 2年前

    Drug compatibilities.

    Drug compatibilities.

    41問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 35問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    35問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    Quinn Karylle Fuentes · 30問 · 2年前

    BACTERIOLOGY 3

    BACTERIOLOGY 3

    30問 • 2年前
    Quinn Karylle Fuentes

    SUSPENSION.

    SUSPENSION.

    Quinn Karylle Fuentes · 45問 · 2年前

    SUSPENSION.

    SUSPENSION.

    45問 • 2年前
    Quinn Karylle Fuentes

    Colloidal.

    Colloidal.

    Quinn Karylle Fuentes · 40問 · 2年前

    Colloidal.

    Colloidal.

    40問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    Quinn Karylle Fuentes · 38問 · 2年前

    BACTERIOLOGY 4 (Rickettsia)

    BACTERIOLOGY 4 (Rickettsia)

    38問 • 2年前
    Quinn Karylle Fuentes

    BACTERIOLOGY.

    BACTERIOLOGY.

    Quinn Karylle Fuentes · 44問 · 2年前

    BACTERIOLOGY.

    BACTERIOLOGY.

    44問 • 2年前
    Quinn Karylle Fuentes

    Emulsion.

    Emulsion.

    Quinn Karylle Fuentes · 32問 · 2年前

    Emulsion.

    Emulsion.

    32問 • 2年前
    Quinn Karylle Fuentes

    EMULSION

    EMULSION

    Quinn Karylle Fuentes · 42問 · 2年前

    EMULSION

    EMULSION

    42問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    Quinn Karylle Fuentes · 36問 · 2年前

    MEDICAL RELATED PROBLEMS.

    MEDICAL RELATED PROBLEMS.

    36問 • 2年前
    Quinn Karylle Fuentes

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    Quinn Karylle Fuentes · 33問 · 2年前

    MEDICATION RELATED PROBLEMS.

    MEDICATION RELATED PROBLEMS.

    33問 • 2年前
    Quinn Karylle Fuentes

    Mycology.

    Mycology.

    Quinn Karylle Fuentes · 30問 · 2年前

    Mycology.

    Mycology.

    30問 • 2年前
    Quinn Karylle Fuentes

    Mycology 2.0

    Mycology 2.0

    Quinn Karylle Fuentes · 34問 · 2年前

    Mycology 2.0

    Mycology 2.0

    34問 • 2年前
    Quinn Karylle Fuentes

    m

    m

    Quinn Karylle Fuentes · 15問 · 2年前

    m

    m

    15問 • 2年前
    Quinn Karylle Fuentes

    ppr

    ppr

    Quinn Karylle Fuentes · 25問 · 2年前

    ppr

    ppr

    25問 • 2年前
    Quinn Karylle Fuentes

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    Quinn Karylle Fuentes · 20問 · 2年前

    MEDICAL DEVICES.

    MEDICAL DEVICES.

    20問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    Quinn Karylle Fuentes · 86問 · 2年前

    Pharmacokinetics. (1.0)

    Pharmacokinetics. (1.0)

    86問 • 2年前
    Quinn Karylle Fuentes

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    Quinn Karylle Fuentes · 19問 · 2年前

    Pharmacokinetics (1.2)

    Pharmacokinetics (1.2)

    19問 • 2年前
    Quinn Karylle Fuentes

    Introduction.

    Introduction.

    Quinn Karylle Fuentes · 17問 · 2年前

    Introduction.

    Introduction.

    17問 • 2年前
    Quinn Karylle Fuentes

    Introduction of biochemistry

    Introduction of biochemistry

    Quinn Karylle Fuentes · 76問 · 2年前

    Introduction of biochemistry

    Introduction of biochemistry

    76問 • 2年前
    Quinn Karylle Fuentes

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    Quinn Karylle Fuentes · 56問 · 2年前

    Intro medicanal chemistry.

    Intro medicanal chemistry.

    56問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 75問 · 2年前

    Carbohydrates

    Carbohydrates

    75問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates 1.1

    Carbohydrates 1.1

    Quinn Karylle Fuentes · 31問 · 2年前

    Carbohydrates 1.1

    Carbohydrates 1.1

    31問 • 2年前
    Quinn Karylle Fuentes

    Detect and quality variation.

    Detect and quality variation.

    Quinn Karylle Fuentes · 56問 · 2年前

    Detect and quality variation.

    Detect and quality variation.

    56問 • 2年前
    Quinn Karylle Fuentes

    INTRODUCTION

    INTRODUCTION

    Quinn Karylle Fuentes · 98問 · 2年前

    INTRODUCTION

    INTRODUCTION

    98問 • 2年前
    Quinn Karylle Fuentes

    lab (1-2)

    lab (1-2)

    Quinn Karylle Fuentes · 15問 · 2年前

    lab (1-2)

    lab (1-2)

    15問 • 2年前
    Quinn Karylle Fuentes

    lab 1-2

    lab 1-2

    Quinn Karylle Fuentes · 14問 · 2年前

    lab 1-2

    lab 1-2

    14問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    Quinn Karylle Fuentes · 45問 · 2年前

    Pharmaceutical chemistry.

    Pharmaceutical chemistry.

    45問 • 2年前
    Quinn Karylle Fuentes

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    Quinn Karylle Fuentes · 35問 · 2年前

    Pharmaceutical chemistry 1.1

    Pharmaceutical chemistry 1.1

    35問 • 2年前
    Quinn Karylle Fuentes

    Unit 3.

    Unit 3.

    Quinn Karylle Fuentes · 39問 · 2年前

    Unit 3.

    Unit 3.

    39問 • 2年前
    Quinn Karylle Fuentes

    Histamin and kinins

    Histamin and kinins

    Quinn Karylle Fuentes · 70問 · 2年前

    Histamin and kinins

    Histamin and kinins

    70問 • 2年前
    Quinn Karylle Fuentes

    PUD.

    PUD.

    Quinn Karylle Fuentes · 45問 · 2年前

    PUD.

    PUD.

    45問 • 2年前
    Quinn Karylle Fuentes

    ..

    ..

    Quinn Karylle Fuentes · 61問 · 2年前

    ..

    ..

    61問 • 2年前
    Quinn Karylle Fuentes

    Lipids.

    Lipids.

    Quinn Karylle Fuentes · 67問 · 2年前

    Lipids.

    Lipids.

    67問 • 2年前
    Quinn Karylle Fuentes

    lipids.

    lipids.

    Quinn Karylle Fuentes · 71問 · 2年前

    lipids.

    lipids.

    71問 • 2年前
    Quinn Karylle Fuentes

    LAB ✨

    LAB ✨

    Quinn Karylle Fuentes · 93問 · 2年前

    LAB ✨

    LAB ✨

    93問 • 2年前
    Quinn Karylle Fuentes

    Drug discovery.

    Drug discovery.

    Quinn Karylle Fuentes · 87問 · 2年前

    Drug discovery.

    Drug discovery.

    87問 • 2年前
    Quinn Karylle Fuentes

    disease of lipids.

    disease of lipids.

    Quinn Karylle Fuentes · 13問 · 2年前

    disease of lipids.

    disease of lipids.

    13問 • 2年前
    Quinn Karylle Fuentes

    Intro (identify structure)

    Intro (identify structure)

    Quinn Karylle Fuentes · 57問 · 2年前

    Intro (identify structure)

    Intro (identify structure)

    57問 • 2年前
    Quinn Karylle Fuentes

    Carbohydrates

    Carbohydrates

    Quinn Karylle Fuentes · 98問 · 2年前

    Carbohydrates

    Carbohydrates

    98問 • 2年前
    Quinn Karylle Fuentes

    Dynamic.

    Dynamic.

    Quinn Karylle Fuentes · 96問 · 2年前

    Dynamic.

    Dynamic.

    96問 • 2年前
    Quinn Karylle Fuentes

    Unit 1

    Unit 1

    Quinn Karylle Fuentes · 32問 · 2年前

    Unit 1

    Unit 1

    32問 • 2年前
    Quinn Karylle Fuentes

    問題一覧

  • 1

    The processes of a drug from the systemic circulation to organs and tissue involve its permeation through membrane barriers and are dependent on its solubility (recall that only nonionized drugs cross biomembranes), the rate of blood flow to the tissues, and the binding of drug molecules to plasma proteins.

    Distribution

  • 2

    What are the factors affecting distribution?

    Rate and Extent Distribution

  • 3

    -Membrane permeability - Capillary wall structure - Drug’s pKa and blood pH - Blood Perfusion

    Rate of distribution.

  • 4

    - Lipid solubility - pH-pKa - Tissue localization - Plasma-protein binding

    Extent of distribution.

  • 5

    DRUG MOLECULES are carried by the blood to the target site (receptors) and to nonreceptor tissues

    Distribution.

  • 6

    DRUG + PROTEIN (ALBUMIN) = DRUG ALBUMIN COMLEX (pharmacologically inactive)

    Protein binding capacity.

  • 7

    drug that is unbound to plasma proteins. Only the “unbound” or free drug is available to distribute out of blood vessels and act on the body cells to elicit the desired effect

    Free drug.

  • 8

    - Major plasma protein component . - Reversible drug binding . - Acidic drugs.

    Albumin.

  • 9

    Alpha-1 Acid Glycoprotein (AAG) and Globulin

    Basic drugs.

  • 10

    - macromolecular complexes of lipids + proteins - Binds drugs when albumin sites become saturated

    Lipoprotein

  • 11

    May bind both endogenous and exogenous compounds

    RBC

  • 12

    May be responsible for the transport of certain endogenous substances such as corticoste

    Globulin

  • 13

    The most abundant protein in human blood plasma

    Albumin

  • 14

    produced in the liver. soluble and monomeric.

    Albumin

  • 15

    Responsible for maintaining the osmotic pressure of the blood.

    Albumin

  • 16

    Elimination half life 17 – 18 days Reversible binding Synthesized in the liver

    Albumin

  • 17

    MW 44,000Da Low plasma concentration(0.4- 1%) binds primarly basic (cationic) drugs.

    A-acid glycoprotein

  • 18

    Macromolecular complexes lipids and protein Classified accdg. to their density and separation in the ultracentrifuge.

    Lipoprotein

  • 19

    Responsible for the transport of plasma liquids to the liver. Resp. for binding if albumin is saturated

    Lipoprotein

  • 20

    45 % of the total volume May bind both endogenous and exogenous compounds.

    Erythrocytes

  • 21

    Αβγ globulins Transport certain endogenous subs (corticosteroid) Ppt in both distilled water and 50% sat. Ammonium SO4

    Globulins

  • 22

    -Physicochemical nature - Concentration in the body

    Drug

  • 23

    - Qty available for binding - Quality of protein synthesized - Affinity between drug & protein

    Protein

  • 24

    - Competition at binding sites - Alteration of the protein by a substance that modifies the affinity of a drug for the protein

    Drug interactions

  • 25

    Tissues with decrease regional blood flow (bones, adipose tissues, middle ear)

    Blood flow

  • 26

    Areas of high blood flow

    Heart, liver, kidney and brain

  • 27

    Areas of low blood flow:

    Muscle, skin, fat and bone

  • 28

    BBB and PLACENTAL BARRIER Allows only non-ionized, unbound drug to enter brain.

    Ability to cross membranes.

  • 29

    The chemical process by which the body converts an agent from its original form to a more water-soluble form that can be excreted

    Metabolism

  • 30

    most important site of drug metabolism, but it may also occur in renal tissue, lungs, plasma or intestinal mucosa.

    Liver

  • 31

    the major site of metabolism for the majority of drugs

    Liver

  • 32

    hydrolysis, mainly of esters

    Plasma and body fluids

  • 33

    metabolism of endogenous transmitters and drugs with similar structures

    Nerve terminals

  • 34

    responsible for pre-systemic metabolism of many drugs

    Mucosal cells

  • 35

    metabolize some drugs

    Kidney, lungs and muscle

  • 36

    capable of glucuronidation of morphine

    Brain

  • 37

    metabolism of several drugs and hydrolysis of glucuronide metabolites.

    Intestinal bacteria.

  • 38

    metabolic conversion of drugs, generally to less active compounds but sometimes to isoactive or more active forms.

    Biotransformation.

  • 39

    the phenomenon whereby drugs may be metabolized following absorption before reaching systemic circulation

    First pass effect

  • 40

    Include oxidation (especially by the cytochrome P45- group of enzymes also called mixed function oxidases), reduction, deamination and hydrolysis

    Phase 1

  • 41

    Reactions that convert the parent drug to a more polar (watersoluble) or more reactive product by unmasking or inserting a polar functional group such as -OH, -SH, or -NH

    Phase 1.

  • 42

    Polar functional groups are introduced into the molecule or unmasked by

    Oxidation, reduction and hydrolysis

  • 43

    -loss of electrons - reducing agents - dehydrogenation - increase in oxidation state

    Oxidation

  • 44

    A heme protein with iron protoporphyrin IX as the prosthetic group

    Cytochrome 450

  • 45

    These enzymes require a reducing agent (NADPH) and molecular oxygen (one oxygen atom appearing in the product and the other in the form of water)

    Microsomal oxidation

  • 46

    Mono Amine Oxidase (ex. Serotonin, Epinephrine, Norepinephrine, Dopamine, Tyramine)

    CYP independent oxidation

  • 47

    Xanthine oxidase

    CYP independent oxidation

  • 48

    -gain of electrons - oxidizing agents - hydrogenation - decrease in oxidation state

    Reduction

  • 49

    Nitro reduction (ex)

    Chlorampenicol

  • 50

    Carbonyl reduction (ex)

    Naloxone

  • 51

    Azo reduction. (ex)

    Protonsil (Sulfonamides).

  • 52

    Dehalogenation.( ex)

    Halothane

  • 53

    Splitting of large molecule involving water as solvent

    Hydrolysis

  • 54

    Examples of hydrolysis.

    Amide and Ester.

  • 55

    Hydrolysis used for?

    Local anesthetic

  • 56

    Synthetic reactions that involve addition (conjugation) of subgroups to -OH, -NH 2, and -SH functions on the drug molecule.

    Phase 2.

  • 57

    The subgroups that are added include glucuronate, acetate, glutathione, glycine, sulfate, and methyl groups.

    Phase 2.

  • 58

    Most of these groups are relatively polar and make the product less lipid-soluble than the original drug molecule.

    Phase 2.

  • 59

    This metabolism phase reaction is responsible for the formation of the final metabolic product of the drug to be excreted

    Phase 2.

  • 60

    relatively water soluble and readily excretable biologically inactive and nontoxic

    Phase 2.

  • 61

    Do not generally increase water solubility but mainly to serve to terminate or attenuate pharmacological activity.

    Phase 2.

  • 62

    a condensation of the drug or its primary metabolite with glucoronic acid.

    Glucoronidation

  • 63

    The reaction requires activation of glucoronic acid by synthesis of UDPGA

    Glucoronidation

  • 64

    Drugs that compete for glucuronidation or reduce the already low glucuronyl transferase activity can precipitate Kernicterus.

    True.

  • 65

    Caused by Chloramphenicol given to neonates

    Grey baby syndrome.

  • 66

    Caused by Chloramphenicol given to neonates

    Grey baby syndrome.

  • 67

    The human newborn is already capable of sulfate conjugation but this pathway becomes easily saturated due to limited sulfate pool

    Sulfation.

  • 68

    The sulfate pool in the organism is limited and easily depleted. PAPS transfer the sulfate to the drug molecule in the soluble fraction of the cell.

    Sulfation.

  • 69

    Sulfation.

    Birth.

  • 70

    1st week

    Oxidation and reduction.

  • 71

    1 month .

    acetylation

  • 72

    2 months.

    Glucoronidation

  • 73

    3 months.

    Glycerin conjugate.

  • 74

    most common endogenous amine for conjugation with organic acids.

    Glycerin

  • 75

    Takes place usually in the mitochondrial fraction. However, bile acids are conjugated with glycine in the microsomal fraction

    Glycerin conjugation.

  • 76

    Newborns and aged have a reduced glycine pool

    Glycerin conjugation.

  • 77

    available in man for conjugation with organic acids, such as phenylacetic and related acids.

    Glutamine

  • 78

    for glutamine conjugation is localized in the liver and kidney

    Acylating enzyme.

  • 79

    Conjugation by acetylation of aromatic primary amines, aliphatic amines, amino acids, hydrazines (-NHNH2), hydrazides (-CONHNH2) and sulfonamides occurs in many tissues

    True.

  • 80

    The newborn is not capable of acetylation. The presence of the various acetyl transferases is genetically determined (slow acetylation and fast acetylators

    True.

  • 81

    Side effect of Procainamide SLE (systemic lupus erythematosus

    Butterfly rash.

  • 82

    It is only a minor pathway for conjugating drugs and xenobiotics.

    Methylation.

  • 83

    It generally does not lead to polar or water-soluble metabolites, except when it creates a quaternary ammonium derivative.

    Methylation.

  • 84

    Most methylated products tend to be pharmacologically inactive except for some.

    True.

  • 85

    Drug or chemical-stimulated increase in enzyme activity.

    Enzyme induction.

  • 86

    Alteration in the enzyme activity in liver microsomes resulting in a faster rate of metabolism not a disease; it is an adaptation of the body to exogenous material

    Enzyme induction.

  • 87

    A drug that stimulates its own metabolism

    Auto induction.

  • 88

    Phenobarbital is given repeatedly its metabolism is increased

    Auto induction.

  • 89

    Types of emzye induction.

    Auto and foreign.

  • 90

    one enzyme inducer stimulate the rate of metabolism of another drug

    Foreign induction.

  • 91

    If a dose of hexobarbital is then given its metabolism is also increased

    Foreign induction.

  • 92

    May be due to substrate competition or due to direct inhibition of drug metabolizing enzyme

    Enzyme inhibition.

  • 93

    ↓enzyme↓ metabolism ↑ effect

    Enzyme inhibition.

  • 94

    ↑enzymes ↑ metabolism ↓ effect

    Enzyme induction.

  • 95

    the final elimination of the drug substance or its metabolites from the body such as through: 1) The kidney (urine) 2) intestines (feces) 3) skin (sweat) 4) saliva, and/or milk

    Excretion

  • 96

    Located in the peritoneal cavity and most important organ for excretion

    Kidney

  • 97

    -maintain normal fluid volume - maintain salt and water balance with 2 endocrine function

    Kidney

  • 98

    Responsible for the removal of metabolic waste and the maintenance of water and electrolyte balance

    Nephrons

  • 99

    Anions, cations, non-ionized molecules with lipophilic polar groups & those with MW>500

    Biliary excretion

  • 100

    - For drugs poorly absorbed in the intestines - Organic acids & organic bases à active transport - Consider biliary recycling

    Biliary Excretion